Improving Keloids Using Targeted Ultraviolet-B Irradiation
Not Applicable
Completed
- Conditions
- Keloid
- Interventions
- Device: NB-UVB
- Registration Number
- NCT03160053
- Lead Sponsor
- Johns Hopkins University
- Brief Summary
Treatment of keloids with targeted Ultraviolet-Beta (UVB) radiation will improve the clinical appearance and induration of lesions.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2
Inclusion Criteria
- Participants must be 18 years old or over
- Participants must have a diagnosis of keloid
- No treatment with topical or intralesional steroids for 1 month prior to study
Exclusion Criteria
- Patients who are unable to provide informed consent
- A history of photosensitivity, lupus erythematosus, porphyria or current use of a known photosensitizing drug
- Unwillingness to stop with topical or intralesional steroids for 1 month prior to study
- A history of malignant melanoma
- A history of radiation therapy to area of interest
- Subjects who self-report that they are pregnant or nursing
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Treatment Group NB-UVB Keloids that were randomized to the treatment group, were exposed to Narrowband-UVB (NB-UVB). Targeted UVB will be delivered to the keloid for up to 16 weeks using the Lumera UVB light phototherapy device (Daavlin, Bryan Ohio, USA).The affected skin will be irradiated using a hand-held fiber optic cable with an adjustable aperture.
- Primary Outcome Measures
Name Time Method Clinical Appearance As Assessed by the Patient and Observer Scar Assessment (POSAS) Scale 16 weeks Investigators will evaluate the pre- and post-study clinical photographs of all participants. The grading investigator will grade the degree of improvement using the POSAS scale to measure the clinical appearance of the keloids
- Secondary Outcome Measures
Name Time Method